Drug Profile
Paclitaxel controlled-release - BTG
Alternative Names: DTS-301; Genexol/ReGel; OncoGel; Paclitaxel aqueous gel injectionLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator BTG
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma; Oesophageal cancer
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 07 Apr 2011 Discontinued - Phase-II for Oesophageal cancer in European Union (Intratumoural)
- 07 Apr 2011 Discontinued - Phase-II for Oesophageal cancer in India (Intratumoural)